Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Debt: 2020-2022

  • RedHill Biopharma's Total Debt rose 37.79% to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year increase of 37.79%. This contributed to the annual value of $115.2 million for FY2022, which is 37.79% up from last year.
  • As of Q4 2022, RedHill Biopharma's Total Debt stood at $115.2 million, which was up 37.79% from $83.6 million recorded in Q4 2021.
  • In the past 5 years, RedHill Biopharma's Total Debt registered a high of $115.2 million during Q4 2022, and its lowest value of $81.4 million during Q4 2020.
  • In the last 3 years, RedHill Biopharma's Total Debt had a median value of $83.6 million in 2021 and averaged $93.4 million.
  • Data for RedHill Biopharma's Total Debt shows a peak YoY skyrocketed of 37.79% (in 2022) over the last 5 years.
  • RedHill Biopharma's Total Debt (Quarterly) stood at $81.4 million in 2020, then grew by 2.74% to $83.6 million in 2021, then spiked by 37.79% to $115.2 million in 2022.
  • Its last three reported values are $115.2 million in Q4 2022, $83.6 million for Q4 2021, and $81.4 million during Q4 2020.